FDA announces new ‘Office of Digital Transformation’

The U.S. Food and Drug Administration has announced the reorganization of the agency’s information technology, data management and cybersecurity functions into the new Office of Digital Transformation (ODT).

According to acting FDA Commissioner Janet Woodcock, M.D., “Good data management, built into all of our work, ultimately helps us meet and advance the FDA’s mission to ensure safe and effective products for American families.”

The office has been realigned to report directly to the FDA commissioner, elevating the office and its functions to agency-level. This reorganization will advance the agency’s information technology transformation with improved data and IT competencies that improve agency operations to support the public health mission.

The reorganization is part of the FDA’s technology and data modernization efforts that began more than two years ago. The reorganization allows the FDA to bring more effective and efficient data and IT management, built on best practices, to streamline and advance FDA operations by reducing duplicative processes, implementing technological efficiencies using projects that deliver the most customer benefits, and promoting shared services within agency offices and centers to strategically and securely further the agency’s regulatory mission.

“By prioritizing data and information stewardship throughout all of our operations,” Woodcock said, “the American public is better assured of the safety of the nation’s food, drugs, medical devices and other products that the FDA regulates in this complex world.”

About the technology and data modernization plans
The FDA has been undertaking a modernization effort since Sept. 2019, with the Technology Modernization Action Plan, which laid the groundwork for the more modern approach to the use of technology for the agency’s regulatory mission, including looking at innovative ways for the review of food safety, medical product applications, and other critical functions.

That was followed by the Data Modernization Action Plan, announced earlier this year, which built upon the successful streamlining and process improvements started in 2019 to identify and execute high-value driver projects for individual centers and for the agency. As part of the establishment of this new office, the agency is also announcing the appointment of Vid Desai as the agency’s new Chief Information Officer.

(To sign up for a free subscription to Food Safety News, click here.)

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Why Isn't Buprenorphine Available at All Pharmacies? thumbnail

Why Isn’t Buprenorphine Available at All Pharmacies?

Opinion > Second Opinions — More access to this life-saving medication is essential by Scott G. Weiner, MD, MPH July 2, 2023 Weiner is an emergency physician. You're dealing with a life-threatening illness that has an effective treatment. The only problem is the medication is only available at about 60% of pharmacies. What now? This
Read More
Novel Long-Lesion DES Sails Through Pivotal Trial thumbnail

Novel Long-Lesion DES Sails Through Pivotal Trial

Meeting Coverage > SCAI — 48-mm Xience stent surprised with low restenosis at 1 year by Crystal Phend, Contributing Editor, MedPage Today May 21, 2023 PHOENIX -- The novel, next-generation Xience drug-eluting stent (DES) with a 48-mm length met the performance bar with a particularly low restenosis rate, the SPIRIT 48 trial showed. The Xience
Read More
Adding Darolutamide: New SOC for Metastatic Prostate Cancer thumbnail

Adding Darolutamide: New SOC for Metastatic Prostate Cancer

New data suggest that adding darolutamide (Nubeqa) onto androgen deprivation therapy (ADT) and docetaxel should become a new standard of care for men with metastatic hormone-sensitive prostate cancer (mHSPC), say investigators reporting results from the phase 3 ARASENS study. The three drug combination significantly reduced the risk of death by 32.5% (hazard ratio [HR], 0.68;…
Read More
Placenta Issues Linked to Newborns' Brain Aberrations in Congenital Heart Disease thumbnail

Placenta Issues Linked to Newborns’ Brain Aberrations in Congenital Heart Disease

Pediatrics > Preventive Care — Study supports hypothesis that placental abnormalities are intertwined with brain development by Nicole Lou, Senior Staff Writer, MedPage Today March 1, 2024 Among babies with severe congenital heart disease (CHD), neurological abnormalities tended to cluster in those who had been exposed to some placental pathology while still in the womb
Read More
Index Of News
Total
0
Share